Medifast, Inc.
MED · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 1.60B | 1.14B | 184.81M | 143.57M | 12.82 |
| 2023 FY | 1.07B | 775.85M | 126.40M | 99.42M | 9.10 |
| 2024 FY | 602.46M | 444.62M | 2.88M | 2.09M | 0.19 |
| 2025 FY | 385.79M | 275.19M | -14.21M | -18.67M | -1.70 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 316.21M | 161.17M | 87.69M | 26.05M | 155.04M |
| 2023 FY | 309.91M | 108.43M | 94.44M | 22.01M | 201.48M |
| 2024 FY | 284.21M | 74.10M | 90.93M | 16.13M | 210.11M |
| 2025 FY | 257.01M | 58.09M | 89.30M | 16.79M | 198.92M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 194.57M | -16.68M | 177.89M | -71.62M | -16.49M |
| 2023 FY | 147.66M | -6.48M | 141.17M | -73.02M | 6.75M |
| 2024 FY | 24.48M | -7.45M | 17.02M | -715.00K | -3.51M |
| 2025 FY | 6.86M | -5.61M | 1.25M | -195.00K | -1.63M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 1.29B | 1.23B | — | — | — |
| 2023 FY | 731.62M | 659.19M | — | — | — |
| 2024 FY | 192.59M | 117.78M | — | — | — |
| 2025 FY | 117.28M | 44.76M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 105.56M | 76.64M | -1.07M | 2.48M | 0.23 |
| 2025 Q3 | 89.41M | 62.16M | -4.08M | -2.26M | -0.21 |
| 2025 Q4 | 75.10M | 52.14M | -7.80M | -18.12M | -1.65 |
| 2026 Q1 | 76.04M | 51.76M | -1.10M | -2.12M | -0.19 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 269.33M | 53.33M | 101.69M | 13.07M | 216.01M |
| 2025 Q3 | 268.21M | 53.50M | 99.53M | 12.26M | 214.71M |
| 2025 Q4 | 257.01M | 58.09M | 89.30M | 16.79M | 198.92M |
| 2026 Q1 | 252.05M | 54.37M | 71.53M | 16.10M | 197.68M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -3.38M | -1.38M | -4.76M | -1.00K | 9.98M |
| 2025 Q3 | 12.11M | -1.36M | 10.75M | — | -2.17M |
| 2025 Q4 | -5.28M | -1.35M | -6.63M | — | -10.22M |
| 2026 Q1 | 260.00K | -1.10M | -836.00K | -87.00K | -17.77M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 154.42M | 65.80M | — | — | — |
| 2025 Q3 | 150.25M | 62.98M | — | — | — |
| 2025 Q4 | 117.38M | 44.87M | — | — | — |
| 2026 Q1 | 112.15M | 56.72M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |